[A21-100] Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V

Last updated 02.11.2021

Project no.:

Commission awarded on 01.08.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with newly diagnosed systemic light chain amyloidosis

Result of dossier assessment:
  • Patients for whom bortezomib + cyclophosphamide + dexamethasone is the best individual choice: hint of minor added benefit.
  • Patients for whom a therapy other than bortezomib + cyclophosphamide + dexamethasone is the best individual choice: added benefit not proven.

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form